- Tytuł:
- The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
- Autorzy:
- Corporate Authors:
- Canadian Uro-Oncology Group
- Źródło:
- BJU international [BJU Int] 2008 Aug 05; Vol. 102 (5), pp. 551-5. Date of Electronic Publication: 2008 May 28.
- Typ publikacji:
- Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasms, Hormone-Dependent/*drug therapyProstatic Neoplasms /*drug therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease Progression ; Docetaxel ; Humans ; Male ; Middle Aged ; Mitoxantrone/administration & dosage ; Neoplasm Metastasis ; Neoplasms, Hormone-Dependent/mortality ; Pain/etiology ; Prednisone/administration & dosage ; Prostate-Specific Antigen/blood ;Prostatic Neoplasms /mortality ; Quality of Life ; Survival Analysis ; Taxoids/administration & dosage ; Treatment Outcome
Czasopismo naukowe